Jideytro nabs FDA approval as second-line treatment in non-small cell lung cancer

The FDA has approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.Zidesamtinib (Jideytro, GSK) is designed to provide highly selective coverage of ROS1 mutations and improved blood-brain-barrier penetration for patients previously treated with a ROS1 kinase inhibitor.